LP-98 / Shanxi Kangbao Bio - LARVOL DELTA

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients (clinicaltrials.gov) - P1/2 | N=40 | Enrolling by invitation | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Human Immunodeficiency Virus • Infectious Disease

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=36 | Completed | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Recruiting ➔ Completed | N=80 ➔ 36 | Trial completion date: Dec 2023 ➔ Apr 2024 | Trial primary completion date: Dec 2023 ➔ Apr 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

Pharmacokinetics and Efficacy of Multiple Dosing of LP-98 for Injection in HIV-infected Patients (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd.

New P1/2 trial • Human Immunodeficiency Virus • Infectious Disease

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of LP-98 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Shanxi Kangbao Biological Product Co., Ltd.

New P1 trial • Human Immunodeficiency Virus • Infectious Disease